IP Library Granted Patent US 7,125,902
Granted Patent B2
US 7,125,902 · App. 10/856,519 · Granted Oct 24, 2006

Methods, compounds, and diagnostics for cancer treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,902
App. No.
10/856,519
Granted
Oct 24, 2006
Kind
B2
Abstract

Methods of treating cancer employing isoxazole derivatives are described. Compounds and methods of using these compounds for isolating and/or detecting binding proteins, which may be indicative of a disease, are also described.

Claims (7)

1. A method for the treatment of colon cancer, lung cancer, leukemia, Kaposi's sarcoma, ovarian cancer, sarcoma, meningioma, intestinal cancer, cancer of the lymph nodes, brain tumors, breast cancer, stomach cancer, cancer of the pancreas, cancer of the prostate, and skin cancer comprising administering to a patient or an animal in need thereof a therapeutically effective amount of a compound having a formula (I):

or a physiologically tolerable salt thereof;

wherein R is selected from the group consisting of —H, 2-Cl, 3-Cl, 4-Cl, 2,4-(Cl) 2 , 2-F, 3-F, 4-F, 2,4-(F) 2 , 2-Br, 3-Br, 4-Br, 2,4-(Br) 2 , 2-CF 3 , 3-CF 3 , 4-CF 3 , 2,4-(CF 3 ) 2 , 2-COOH, 3-COOH, 4-COOH, 2,4-(COOH) 2 , 2-OCH 3 , 3-OCH 3 , 4-OCH 3 , 3,4,5-(OCH 3 ) 3 , 2-NH—CO—CH 2 Cl, 4-NH—CO—CH 2 Cl, 2-NH—CO—CH 2 Br, 4-NH—CO—CH 2 Br, or —CONHCH(COOC 2 H 5 )CH 2 CH 2 COOC 2 H 5 .

2. The method of claim 1 further comprising administering an additional cancer therapeutic agent.

3. The method of claim 2 , wherein said additional cancer therapeutic agent is selected from the group consisting of tumor irradiation, a chemotherapeutic agent, an expression construct comprising a nucleic acid encoding a cancer therapeutic gene and a promoter operative in eukaryotic cells, said nucleic acid being operatively linked to said promoter, and combinations thereof.

4. The method of claim 3 , wherein said chemotherapeutic agent comprises a DNA damaging agent selected from the group consisting of verapamil, podophyllotoxin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, cisplatin, carboplatin, oxaliplatin, and combinations thereof.

5. The method of claim 3 , wherein said irradiation is selected from the group consisting of X-ray radiation, UV-radiation, γ-radiation, microwave radiation, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2007
From: UNITECH PHARMACEUTICALS, INC.
To: GENEBLUE CORPORATION
Reel/Frame 019733/0564 →